Lido Advisors
RLMD icon

Lido Advisors’s Relmada Therapeutics RLMD Stock Holding History

Lido Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$96.8K Hold
13,905
– – ﹤0.01% 1864
2025
Q4 		$27.9K Hold
13,905
– – ﹤0.01% 1908
2025
Q3 		$27.9K Hold
13,905
– – ﹤0.01% 1810
2025
Q2 		$8.35K Hold
13,905
– – ﹤0.01% 1648
2025
Q1 		$3.75K Buy
+13,905
New +$4.61K ﹤0.01% 1505

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Lido Advisors's RLMD Position: Q1 2026 in Review

Lido Advisors held its Relmada Therapeutics (RLMD) position steady in Q1 2026 at 13,905 shares worth $96.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1864.

Lido Advisors first reported a position in RLMD in Q1 2025 and has held it in 5 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Lido Advisors held 13,905 shares of Relmada Therapeutics worth $96.8K as of Q1 2026.
  • Lido Advisors left its Relmada Therapeutics share count unchanged in Q1 2026.
  • Relmada Therapeutics made up ﹤0.01% of Lido Advisors's portfolio in Q1 2026, its #1864 holding.
  • Lido Advisors first reported a position in Relmada Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Lido Advisors's 13F filing for Q1 2026, filed 13 May 2026.